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Abstract
Among the enzymes involved in NAD homeostasis, nicotinamide mononucleotide adenylyltransferases (NMNAT1-3) are
central to intracellular NAD formation. Although NMNAT3 is postulated to be a mitochondrial enzyme contributing to NAD-
dependent organelle functioning, information on endogenous proteins is lacking. We report that in human cells a single
gene nmnat3 localized on chromosome 3 codes for two mRNA splice variants NMNATv1 and FKSG76, whereas the
previously reported NMNAT3v2 transcript is not present. However, NMNAT3v1 and FKSG76 proteins are not detectable,
consistent with the finding that an upstream ORF in their mRNAs negatively regulates translation. NMNAT3v1 transfection
demonstrates that the protein is cytosolic and inactive, whereas FKSG76 is mitochondrial but operates NAD cleavage rather
than synthesis. In keeping with the lack of NMNAT3, we show that extracellular NAD, but not its metabolic precursors,
sustains mitochondrial NAD pool in an ATP-independent manner. Data of the present study modify the scenario of the
origin of mitochondrial NAD by showing that, in human cells, NMNAT3 is absent in mitochondria, and, akin to plants and
yeast, cytosolic NAD maintains the mitochondrial NAD pool.
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Introduction
During the last several years, we witnessed a renewed interest in
the biosynthesis of nicotinamide adenine dinucleotide (NAD) [1,2].
This is due to the understanding that NAD homeostasis is not
exclusively based on redox reactions (i.e. mutual conversion of
NAD into NADH with conservation of the dinucleotide moiety)
but also on the irreversible transformation of NAD into an
expanding array of metabolites endowed with pleiotypic signaling
properties [1,3]. In keeping with this, several NAD-hydrolyzing
enzymes such as poly (ADP-ribose) polymerases (PARPs), mono
(ADP-ribose) transferases, sirtuins and the NADase CD38 have
been identified. A great deal of investigation is now dedicated to
the understanding of the physiological and pathological roles of
these enzymes, with particular attention to development of
pharmacological tools able to modulate their activities for
therapeutic purposes [3–6].
A new concept of NAD homeostasis is that a major mechanism
of regulation of NAD-consuming enzymes is availability of NAD
itself within the different cell compartments [7,8]. The under-
standing that, at variance with what previously envisaged, also
metabolic, NAD-dependent redox reactions are limited by
intracellular NAD concentrations significantly widens the patho-
physiological and therapeutic implications of modulation of
intracellular NAD availability [3]. In mammalian cells, the main
pathway of NAD resynthesis is a two-step metabolic route. It stems
from the conversion of nicotinamide (Nam) into nicotinamide
mononucleotide (NMN) by nicotinamide phosphoribosyl-transfer-
ase, that is followed by the conversion of NMN into NAD by
nicotinamide mononucleotide adenylyltransferase (NMNAT) [5].
At present, three NMNAT isoforms (NMNAT1-3) have been
identified with different kinetic parameters and cellular localiza-
tion [9]. While NMNAT1 is a nuclear enzyme responsible for the
majority of NAD resynthesis [10], and NMNAT2 is a protein
probably docked to the external surface of the endoplasmic
reticulum contributing to cytosolic NAD rescue [11], less is known
about NMNAT3.
NMNAT3 was initially identified by sequence homology with
NMNAT1, cloned and localized in mitochondria, in keeping with
the presence of a mitochondrial targeting sequence (MTS) [9,12].
Catalytic mechanisms of NMNAT3 have been postulated [12,13]
but its functional relevance to NAD homeostasis and cell biology is
almost unknown. This is because information on structural and
catalytic properties of NMNAT3 has been exclusively collected by
means of transient transfection in cultured cells [9,12,14]. Di
Stefano et al. report the endogenous presence of NMNAT3 in red
cells [15] that, however, do not contain mitochondria. On this
basis, the question as to whether NMNAT3 is expressed in
mammalian cells is still open. This is in striking contrast with the
key role of mitochondrial NAD both to energetic metabolism and
more integrated pathophysiological processes such as aging,
obesity and diabetes [16].
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In this light, we attempted to elucidate the functional relevance
of endogenous NMNAT3 to mitochondrial NAD synthesis, with
the aim of adding new information on how NAD homeostasis is
maintained within the organelle.
Materials and Methods
Cell culture conditions and heat shock
HEK293 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 2 mM glutamine, 10% fetal
bovine serum and antibiotics. Cultures were brought to 50–70%
confluence and used for the experiments. Cell cultures were
exposed to NAD, Nam, NMN, nicotinamide riboside (NR),
nicotinic acid (NA) or other compounds directly dissolved in the
culture media. NR was synthesized as described by Yang et al.
[17]. For heat shock experiments, cells were incubated 30 minutes
at 44uC, and then subjected to different periods of recovery at
37uC. Later on, RNA was isolated and retro-transcribed as
described below.
NAD and ATP measurement
NAD contents were quantified by means of an enzymatic
cycling procedure according to Cipriani et al. [18]. Briefly, cells
grown in a 48 well plate were killed with 50 ml HClO41N and then
neutralized with an equal volume of KOH 1N. After the addition
of 100 ml of bicine 100 mM pH 8, 50 ml of the cell extract was
mixed with an equal volume of the bicine buffer containing 23 ml/
ml ethanol, 0.17 mg/ml MTT, 0.57 mg/ml phenazine ethosulfate
and 10 mg alcohol dehydrogenase. Mixture was kept at room
temperature for 20 minutes and then absorbance a 550 nm was
measured. A standard curve allowed quantification of NAD. The
cellular ATP content was measured by means of an ATPlite kit
from PerkinElmer Life and Analytical Sciences (Zaventem,
Belgium).
Cell fractionation and NMNAT activity assay
Mitochondria and nuclei were isolated from cells using a glass/
glass homogenizer in 500 ml of extraction buffer, as described [19].
Briefly, supernatants were first centrifuged at 600 g to obtain
nuclear fraction, and then were centrifuged at 7000 g to obtain the
mitochondrial pellet. For enzymatic assay, cells, nuclear or
mitochondrial fractions were disrupted with 200 ml of lysis buffer
(25 mM Tris/HCl pH 8, 150 mM NaCl, 0.5% Triton-X).
Extracts were incubated for 30 minutes at 37uC in a reaction
mixture containing 50 mM Tris/HCl pH 8, 200 mM NaCl,
1 mM MgCl2 with 1 mM NMN and/or 1 mM ATP. NAD
formation was evaluated using the above-mentioned enzymatic
cycling procedure.
Oxygen Consumption Analysis
Quantitation of oxygen consumption was conducted by means
of the Oxygraph system (Hansatech Instruments, Norfolk, UK).
Cells (250,000) were loaded in the chamber in 400 ml of
respiration buffer (70 mM sucrose, 220 mM mannitol, 2 mM
HEPES, pH 7.4, 5 mM MgCl2, 5 mM K2HPO4, 1 mM EDTA,
and 0.1% bovine serum albumin), and oxygen consumption was
monitored for 10 min at 37uC.
Western and dot blotting
For Western blotting, cells were scraped, collected in Eppendorf
tubes, centrifuged (1500 g/5 min/4uC) and resuspended in lysis
buffer [50 mM Tris pH 7.4, 1 mM EDTA, 1 mM phenylmethyl-
sulfonyl fluoride (PMSF), 4 mg/ml aprotinin and leupeptin, 1%
SDS]. 20–40 mg of protein/lane were loaded. After 4–20% SDS-
PAGE and blotting, membranes (Immobilon-P Millipore, Bedford,
MA) were blocked with phosphate buffered saline (PBS) containing
0.1% Tween–20 and 5% skimmed milk (TPBS/5% milk) and then
probed overnight with primary antibodies (1:1000 in TPBS/5%
milk). Dot blotting was conducted according to standard
procedures with recombinant FKSG76 (kind gift of Prof. Mathias
Ziegler, University of Bergen, Norway). Immunoprecipitation
from mitochondrial or whole cell extracts has been conducted as
reported [20] by means of a rat monoclonal antibody kindly gifted
by Prof. Mathias Ziegler, University of Bergen, Norway. The anti-
PAR monoclonal antibody (10H) and the anti-ubiquitin mono-
clonal antibody were from Alexis (Vinci, Italy). The anti
NMNAT3 polyclonal antibody used for the experiments of
Western and dot blotting was a kind gift of Prof. Giulio Magni
(Universita` Politecnica delle Marche). Membranes were then
washed with TPBS and incubated 1 h in TPBS/5% milk
containing the corresponding peroxidase-conjugated secondary
antibody (1:2000). After washing in TPBS, ECL (Amersham, UK)
was used to visualize the peroxidase-coated bands.
PCR assays, cloning and transfection
Total RNA from HEK293 cells or human tissues was extract by
means of RNeasy mini kit (Qiagen, Germany). Nucleic acid
extracts digested with RNase-free DNase and resulting RNA
quantified. One mg of RNA was retrotranscribed using iScript
(Bio-Rad Milan Italy) amplified with specific primers described in
Table 1. PCR products were separated on 2% agarose gel and the
relative bands were analyzed by means of Sanger sequencing.
Real-Time PCR was performed using Rotor-Gene 3000 (Qiagen
Milan Italy) and the Rotor-Gene TM SYBRH Green PCR Kit
(Qiagen, Milan, Germany). The following primers were used: for
NMNAT1 forward 59-TCCCATCACCAACATGCACC-39 and
reverse 59-TGATGACCCGGTGATAGGCAG-39; NMNA-
T3v1/FKSG76 forward 59-ATGGGAAGAAAGACCTCG-
CAG-39 and reverse 59-AGTTTGCTGTGATGATGCCTC-
39;18S, forward 59-CGGCTACCACATCCAAGGAA-39 and
reverse 59-GCTGGAATTACCGCGGCT-39. Primers were pur-
chased from IDT (Leuven, Belgium). Cloning primers for
NMNAT3v1 were: forward 59- GGTACCGTTATGGGCTAC-
CAGGTCATCCAGGGT-39 and reverse 59- GAACTCGAGC-
TAGCTTGTCTTGCCCTCAGTGC-39. The amplification
product from HEK293 cDNA was cloned into the pcDNA3.1+
vector (Invitrogen, Milan, Italy) containing the FLAG sequence.
HEK 293 cells were transfected with 4 mg of pCDNA3-
NMNAT3v1-FLAG, pFLAG5-FKSG76, mitoPARP1-cd or emp-
ty vectors. Silencing was obtained adopting a double-hit protocol
exposing the cells to 50 nM siRNAs (Dharmacon, Lafayette,
CO, USA) against NMNAT1 or NMNAT3at time 0 and
48 hrs. For cell transfection and silencing the jetPRIMETM kit
Table 1. Primers adopted for RT-PCR experiments as
depicted in Fig. 1A and C.
Primer Sequence
1 59 ATGAAGAGCCGAATACCTGTG 39
2 59 CTAGCTTGTCTTGCCCTCAG 39
3 59 CGAGACTCGCCGAGCGC 39
4 59 CTGGTACATTCCTTATTAATTGGGAGAC 39
5 59 CACCACAGGTACTCGGCTCTTC 39
doi:10.1371/journal.pone.0076938.t001
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(Polyplus, Illkirch, France) was used according to manufacturer’s
instructions.
Evaluation of upstream ORF functional activity
To amplify the 59UTR sequence containing the upstream ORF
(uORF) the following specific primers were used: forward
AGAAGCTTTGCCATGAAGCGGACTGCTGCTC and re-
verse AACCATGGTATCAGGCACATCCACCC for FKSG76,
or forward AGAAGCTTTGCCATGAAGCGGACTGCTG-
CTC and reverse AACCATGGTCCTTATTAATTGGGAGA-
CAAG for NMNAT3v1. To mutagenize the uORF ATG we
amplified with the forward primer AGAAGCTTTGCCGG-
GAAGCGGACTGCTGC containing GGG instead of the ATG
start codon. PCR fragments were cloned into the HindIII and
NcoI sites of the luciferase-expressing pGL3-Promoter Vector
(Promega, Madison, WI) to obtain the following plasmids: pGL3-
FKSG76-uORF, pGL3-FKSG76-Mut-uORF, pGL3-NMNA-
T3v1-uORF or pGL3-NMNAT3v1-Mut-uORF. HEK293 cells
were co-transfected with pGL4,71 plasmid expressing renilla
luciferase used as internal standard. Luciferase assay was
performed as described by Lapucci et al. [21].
Immunocytochemistry
Cells were grown onto glass coverslips and transfected with the
different plasmids. After 48 hrs, cells were washed with PBS and
then fixed with cold ethanol. After 1 h permeabilization and
blocking in PBS 0.3% Triton X-100% containing 20 mg/ml BSA,
cells were incubated for 2 h with PBS containing 5 mg/ml BSA
plus the primary antibody diluted 1:200. Anti-FLAG monoclonal
antibody was from Sigma (Milan, Italy) and anti-PAR monoclonal
antibody (10H) was from Alexis (Vinci, Italy). After extensive
washing, cells were incubated for 45 min with the corresponding
secondary antibody (1:200 in PBS containing 5 mg/ml BSA) and
washed again with PBS and mounted. Imaging was performed
using a Nikon TE2000-U equipped with a Hg fluorescence lamp,
a Photometrics CF mono CCD camera and Metamorph imaging
software.
Evaluation of mitochondrial membrane potential
Mitochondrial membrane potential was evaluated by means of
flow cytometry [18]. Cells transfected with the empty vector or
FKSG76 plasmid were then incubated with TMRE 2.5 nM in
complete DMEM, detached and analyzed at the indicated time
points. Briefly, cells were washed with PBS, incubated with trypsin
(50 ml/0.25%/2 min) and then diluted with 350 ml complete
DMEM. After gentle pipetting, 200 ml of the cell suspension were
further diluted with 400 ml of PBS and analyzed by the flow
cytometer Coulter EPICS XL (Beckman Coulter, Inc) equipped
with the EXPO32 Flow Cytometry ADC software (Beckman
Coulter, Inc). TMRE 2.5 nM was present in all the solutions used
for cell preparation and measurement.
Structural analysis of nmnat3 gene products
The PDB structure 1NUS coded by the ORF FKSG76
(UniProt code Q96T66) was analyzed. The 3D structure
represents a 252 residue chain complexed with the ATP analog
APC and NMN [10]. Structural investigations were drawn with
Swiss PDB Viewer (DeepView) using hydrogen bond detection
tools to evidence structural constraints in the full-length protein
and mutation tools to create the structural variants described in
this work and also provide valid templates for energetic
minimization by the Swiss-Model 3D prediction server. Structures
were also investigated using the fold recognition servers Robetta
and Phyre.
Detection of NAD content by mitoPARP-1cd
Mitochondrial NAD content was evaluated using the mito-
PARP-1cd construct as described [22]. Briefly, cells were
transfected with mitoPARP-1cd and/or FKSG76. After 48 hrs,
PAR formation was evaluated by means of Western blot analysis.
Variations in the extent of detected PAR reflect changes of the
mitochondrial NAD content. Treatment with NAD or its
precursors began 48 hrs prior to PAR analysis.
Data analysis
Data were analysed using WinLTP 1.11 reanalysis program and
the software package GraphPad Prism (version 4.0; GraphPad
Software, San Diego, CA, USA). All numerical data are expressed
as mean 6 SEM. Statistical significance was evaluated using
paired two-tailed Student’s t-test. Differences were considered
significant at p,0.05.
Results
Identification of NMNAT3 variants expressed in human
cells
In an attempt to understand the structure of the gene coding for
NMNAT3, we came across to apparent inconsistencies present in
GenBank. According to Zhang and associates, NMNAT3 is
encoded by the transcript FKSG76 originating from the gene
fksg76 located on chromosome 8 (accession AF345564) [12].
However, an NCBI search localizes nmnat3 on chromosome 3
coding for two different transcript variants called NMNAT3v1
(accession NM_178177.3) and NMNAT3v2 (accession
NM_001200047.1). We therefore attempted to confirm the
presence of fksg76 on chromosome 8 by means of NCBI
nucleotide blast search, and found that the mRNA exclusively
matches with a sequence present on chromosome 3. We then
compared FKSG76, NMNAT3v1 and NMNAT3v2 mRNAs and
found substantial sequence homology (see Fig. 1A for a schematic
representation). Of note, a nucleotide sequence coding for the
mitochondrial targeting sequence (MTS) is present in FKSG76
and NMNAT3v2 mRNAs but absent in that of NMNAT3v1,
thereby suggesting a different intracellular localization of the latter.
To gather additional information on NMNAT3 variant expres-
sion, we attempted to amplify mRNAs of FKSG76, NMNAT3v1
and NMNAT3v2 from cDNA of HEK293 cells by means of RT-
PCR and specific primers (Table 1). We first used primers
putatively amplifying the entire ORF of FKSG76 and
NMNAT3v2 (that would have different molecular weights, see
Fig. 1A), and found that only the amplification product with the
expected molecular weight of FKSG76 was obtained, but not
NMNAT3v2 (Fig. 1B). NMNAT3v2 transcripts were also absent
in human tissues such as brain, skeletal muscle and kidney
(Fig. 1B). Next, to check for the presence of NMNAT3v1 mRNA,
we designed a forward primer annealing within its 59UTR, and a
reverse one annealing on a region encompassing the start codon
(Fig 1C). We found an amplification product of the expected
molecular weight (Fig. 1D), that, upon Sanger analysis, confirmed
the sequence of NMNAT3v1 present in GenBank. In light of the
apparent mislocalization of fksg76 on chromosome 8 (see above),
and the high degree of sequence homology between NMNAT3v1
and FKSG76 (Fig. 1A), we then speculated that these transcripts
could be splice variants. Consistent with this hypothesis, when we
used the above-mentioned forward primer binding to the 59UTR
of NMNAT3v1 and a reverse one binding inside the MTS of
NMNAT3 and Mitochondrial NAD
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Figure 1. Expression of NMNAT3 mRNA variants in human cells. (A) Schematic representation of the ORF of FKSG76, NMNAT3v1 and
NMNAT3v2. Colors represent different homology domains. MTS, mitochondrial targeting sequence. Annealing position of primers 1 and 2 (Table 1)
used to amplify the ORF of FKSG76 and NMNAT3v2 is shown. (B) Semiquantitative PCR showing the presence of the band of 759 bp related to
FKSG76 ORF and the absence of that of 491 bp related to amplification of NMNAT3v2 ORF in HEK293 cells and human brain, skeletal muscle and
kidney tissues. (C) Schematic representation of a portion of NMNAT3v1 and FKSG76 transcripts containing their 59UTR. Colors represent homology
domains. Annealing position of primers 3, 4 and 5 (Table 1) used to amplify the fragments of FKSG76 and NMNAT3v2 is shown. (D) Semiquantitative
PCR showing the presence of the expected bands of 152 and 147 bp related to amplification of the regions of NMNAT3v1 and FKSG76 shown in (C).
(E) Schematic reconstruction of the pre-mRNA structure from which FKSG76 and NMNAT3v1 transcripts originate by alternative splicing. Colors
NMNAT3 and Mitochondrial NAD
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FKSG76 (Fig. 1C), a fragment of 147 bp was obtained (Fig. 1D).
The amplification product showed the expected 59UTR sequence
identical to that of NMNAT3v1 and the MTS sequence of
FKSG76 plus a fragment of 39 bp comprised between these two
regions (Figure S1). These data taken together indicate that
nmnat3 on chromosome 3 codes for a pre-mRNA from which
FKSG76 and NMNAT3v1 but not NMNAT3v2 transcripts
originate by alternative splicing (Fig. 1E).
Real time PCR showed that NMNAT3v1 and FKSG76
mRNAs were differently transcribed in HEK293 cells and human
tissues, with FKSG76 transcripts showing high levels in brain and
kidney (Fig. 1F).
Effect of NMNAT1 and 23 silencing on cellular NMNAT
activity
As mentioned above, functional relevance of endogenous
NMNAT3 to cellular and mitochondrial NAD homeostasis is
currently unknown. Thus, to gather insights into the contribution
of NMNAT3 to NAD homeostasis, we silenced NMNAT3 by
means of siRNA designed to reduce transcripts of both FKSG76
and NMNAT3v1. We also evaluated the effects of NMNAT1
silencing. Fig 2A and B show that siRNAs for NMNAT1 or
NMNAT3 drastically reduced transcript levels after 72 hrs. We
therefore adopted an enzymatic assay measuring NAD formation
from NMN and ATP to check whether silencing of NMNAT1 or
23 reduced cellular NMNAT activity. The assay was specific for
NMNAT activity being able to detect NAD formation by a whole
cellular homogenate only in the presence of added ATP and NMN
(Fig. 2C). Of note, we used HEK293 cells because they express
negligible transcripts for NMNAT2 [9], thereby allowing to
ascribe their NMNAT activity to NMNAT1 and 23 only. We
found that cellular NMNAT activity was significantly reduced in
cells subjected to NMNAT1 but not NMNAT3 silencing (Fig. 2D).
In keeping with the nuclear localization of NMNAT1, subcellular
evaluation of NMNAT activity showed that only the nuclear
fraction was depleted of enzymatic activity in cells challenged with
siRNA for NMNAT1. Conversely, no differences in NMNAT
activity were found in nuclear or mitochondrial fractions of cells
exposed to NMNAT3 silencing (Fig. 2E). As evidence of purity of
the subcellular fractions, Western blotting demonstrated exclusive
localization of PARP-1 and VDAC in the nuclear and mitochon-
drial extracts, respectively (Fig. 2F). Data suggest that NMNAT3
activity does not contribute to mitochondrial NMNAT activity.
According to this assumption, we found that HeLa cells showed
levels of mitochondrial NMNAT activity analogous to those of
HEK293 cells, despite lack of NMNAT3 transcripts (Fig. 2G).
Effect of overexpression of NMNAT3 isoforms on cellular
NMNAT activity and NAD homeostasis
To obtain further insights on the effect of the two NMNAT3
isoforms on NAD homeostasis, we next investigated the impact of
FKSG76 or NMNAT3v1 transfection on various cellular param-
eters. Transcripts for FKSG76 or NMNAT3v1 increased about
600- and 2400-fold in transfected cells (Fig. 3A). By means of a
polyclonal antibody raised against recombinant NMNAT3 [15],
we then checked for expression of the two NMNAT3 isoforms in
control or transfected HEK cells. By means of Western blotting,
we found that protein expression of both FKSG76 and
NMNAT3v1 did not reach detection limit in control cells. Similar
results were obtained in extracts from human cell lines such as
HeLa (cervix), HCT116 (colon), fibroblasts and HepG2 (liver)
(Fig. 3B). Conversely, bands of the expected molecular weight of
27 and 24 kDa appeared in extracts from cell transfected with
FKSG76 and NMNAT3v1, respectively (Fig. 3B). Intracellular
distribution of the two tagged NMNAT3 variants was also
evaluated by anti-FLAG immunocytochemistry. In keeping with
the exclusive presence of the MTS sequence in FKSG76 (Fig. 1C),
NMNAT3v1 was evenly distributed throughout the cell, con-
versely, as previously reported [9], FKSG76 showed a mitochon-
drial localization (Fig. 3C).
We then investigated the contribution of NMNAT3v1 or
FKSG76 overexpression to cellular NMNAT3 activity. NMNAT
activity was not increased in cells transfected with NMNAT3v1,
whereas an almost 800-fold increase was evident in those
transfected with FKSG76 (Fig. 3D). A subsequent in silico analysis
(see Material and Methods) of NMNAT3v1 3D structure revealed
that the protein lacks the region required to bind and orient ATP
for enzymatic catalysis (Fig. 3E), thereby explaining why NMNAT
activity is not increased in cells transfected with NMNAT3v1.
Consistently, NAD contents did not change in NMNAT3v1-
transfected cells. Unexpectedly, however, FKSG76 overexpressing
cells showed almost half of the basal cellular content of NAD
(Fig. 4A).
To understand whether FKSG76 overexpression reduced
mitochondrial NAD content, we took advantage of a recent
method developed to indirectly quantify NAD levels within the
organelle [22]. Specifically, we evaluated NAD-dependent poly
(ADP-ribose) (PAR) content in cells transfected with a mitochon-
drially-targeted catalytic domain of PARP-1 (mitoPARP1cd) that
leads to substantial PAR formation within mitochondria. By
means of Western blotting, we found that PAR content drastically
increased in mitoPARP1cd-transfected cells, and that this increase
was completely abrogated in those co-transfected with FKSG76
(Fig. 4B and C). Immunocytochemistry confirmed prevention of
mitochondrial PAR formation by FKSG76 (Fig. 4D). Given that
mitochondrial NAD is a key determinant of organelle bioenerget-
ics, we evaluated the effect of FKSG76 transfection on mitochon-
drial membrane potential and oxygen consumption. In keeping
with reduced mitochondrial NAD content, cells overexpressing
FKSG76 showed reduced mitochondrial membrane potential
(Fig 4E) and oxygen consumption (Fig. 4F and G).
Further attempts to identify endogenous NMNAT3
expression
To rule out the possibility of excessive FKSG76 dilution in cell
extracts, we attempted to immunoprecipitate the protein from
mitochondrial extracts by means of a rat monoclonal antibody
raised against FKSG76. As shown in Fig. 5A, FKSG76 was not
detected neither in the input mitochondrial extract nor in the
immunoprecipitate. Conversely, the protein was present in the
immunoprecipitate from FKSG76-transfected cells. Dot blot
analysis of the antibody used to detect FKSG76 and NMNAT3v1
revealed that threshold sensitivity for FKSG76 was in the range of
0.5 ng (Fig. 5B). In depth analysis of the 59UTR regions of
FKSG76 and NMNAT3v1 mRNAs revealed the presence of an
upstream ORF (uORF) in both transcripts (Figure S1). uORFs
impair translational efficiency of the downstream coding sequence
represent homology domains. (F) Comparative analysis of FKSG76 and NMNAT3v1 transcript levels in different human tissues. Agarose gels are
representative of at least 4 independent experiments. In (F) columns represent the mean 6 SEM of 3 RT-PCR experiments with different human
samples.
doi:10.1371/journal.pone.0076938.g001
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Figure 2. Effect of NMNAT1 or23 silencing on cellular NMNAT activity. (A) Semiquantitative PCR showing silencing of NMNAT1 or NMNAT3
by their respective siRNAs. Note that for NMNAT3 siRNAs able to anneal a sequence present in both NMNAT3v1 and FKSG76 have been used. For
NMNAT3 PCR, a sequence present in both NMNAT3v1 and FKSG76 has been amplified. (B) Real-time PCR analysis of the effect of NMNAT3v1 or
NMNAT3 and Mitochondrial NAD
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because it can lead to ribosome stalling and mRNA decay [23,24].
Thus, we studied the functional effects of the uORFs found in
FKSG76 and NMNAT3v1. To this end, we cloned the 59UTR
fragments of FKSG76 and NMNAT3v1 bearing either the wild
type uORF or a mutagenized one (converting the ATG into GGG)
into luciferase expression vectors (see Fig. 5C). Remarkably,
disruption of the wild type uORF significantly increased luciferase
expression (Fig. 5D). These findings suggest that uORFs of
FKSG76 silencing. (C) NMNAT activity in whole HEK cell extracts and different combinations of the substrates. (D) Effect of NMNAT1 or NMNAT3
silencing on cellular NMNAT activity. (E) Effect of NMNAT1 or NMNAT3 silencing on nuclear or mitochondrial NMNAT activity. Nuclear and
mitochondrial NMNAT activities were 24306390 and 3767 Fmol/mg prot/309, respectively. (F) Western blotting evaluation of PARP-1 and VDAC in
the nuclear and mitochondrial fractions of control and silenced HEK293 cells. (G) NMNAT3 transcript levels and mitochondrial NMNAT activity in HeLa
and HEK cells. In (A) and (G) an experiment representative of 5 is shown. Columns/points represent the mean 6 SEM of at least 4 experiments. **
p,0.01; *** p,0.001 vs control (Student’s t test).
doi:10.1371/journal.pone.0076938.g002
Figure 3. Expression, intracellular localization and structure of transfected FKSG76 and NMNAT3v1. (A) Fold increase of mRNA for
NMNAT3v1 or FKSG76 upon transfection of the respective expression plasmids. (B) Western blotting analysis of NMNAT3v1 or FKSG76 expression in
different cell types as well as NMNAT3v1- and FKSG76-transfected HEK cells. Tubulin is shown as loading control. (C) Immunocytochemical
visualization of intracellular distribution of transfected FKSG76 or NMNAT3v1 by means of anti-FLAG antibody. (D) Whole cell NMNAT activity in
NMNAT3v1 or FKSG76 transfected cells. (E) Structure of FKSG76 and NMNAT3v1. The ATP-binding domain absent in NMNAT3v1 is shown in green in
FKSG76. ATP-binding residues are shown in yellow. The orientation of ATP (red) bound into the catalytic site is also shown. Columns represent the
mean 6 SEM of 3 (A) and 4 (D) experiments. Western blotting and Immunocytochemistry are representative of 4 independent experiments.
*** p,0.001 vs control (Student’s t test).
doi:10.1371/journal.pone.0076938.g003
NMNAT3 and Mitochondrial NAD
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FKSG76 and NMNAT3v1 transcripts impair their translation, in
keeping with our inability to detect the respective proteins under
control conditions.
Thus, in an attempt to boost FKSG76 and NMNAT3v1
expression, we exposed HEK cells to different stimuli. We first
reasoned that their undetectable expression levels might be due to
rapid proteasome-dependent degradation. Fig. 5E and 5F indicate
that, upon exposure of HEK cells to the proteasome inhibitor
MG132, intracellular ubiquitin levels linearly increased with time,
indicating efficacy of the drug. Yet, we did not detect expression of
FKSG76 or NMNAT3v1 in cells exposed to MG132 (Fig. 5G).
Recent findings demonstrate that Drosophila NMNAT behaves
as a chaperone protein and can be induced by heat shock [25,26].
To investigate whether human NMNATs are inducible proteins,
we then studied the effect of heat shock on their transcripts. As
shown in Fig 5H 44uC/309 heat shock did not affect transcript
levels for NMNAT3 (primers able to amplify both FKSG76 and
NMNAT3v1 were used) or NMNAT1, and22, thereby ruling out
that NMNATs are inducible proteins in human cells.
Effect of exogenous NAD and its precursors on cellular
and mitochondrial NAD content in FKSG76-
overexpressing cells
Although NMNAT3 is thought to contribute to mitochondrial
NAD homeostasis, data of the present study challenge this
scenario. Recent reports demonstrate that exogenous NAD
increases the mitochondrial dinucleotide pool [8,27]. We therefore
Figure 4. Effect of NMNAT3v1 or FKSG76 transfection on cellular or mitochondrial NAD and membrane potential. (A) Whole cellular
NAD content in control, NMNAT3v1- and FKSG76-transfected cells. Basal NAD content was 12.662 nmol/mg prot. (B) Western blotting evaluation of
poly(ADP-ribose) (PAR) formation in HEK cells under control conditions or after transfection of FKSG76 and/or PARP1-cd. Tubulin is shown as loading
control. (C) Densitometric evaluation of PAR formation shown in (B). (D) Immunocytochemical localization of PAR in HEK cells under control
conditions or after transfection of FKSG76 and/or mitoPARP1cd. (E) Effect of FKSG76 transfection on mitochondrial membrane potential. (F)
Representative experiment of the effect of FKSG76 transfection on oxygen consumption. The arrow indicates the time when cells were added to the
respiration buffer. (G) Oxygen consumption rate in control or FKSG76-transfected cells. Columns represent the mean 6 SEM of 4 (A), 5 (C) and 3 (G)
experiments. Western blotting and immunocytochemistry are representative of 5 and 2 experiments, respectively.* p,0.05; ** p,0.01; *** p,0.001
vs control (Student’s t test).
doi:10.1371/journal.pone.0076938.g004
NMNAT3 and Mitochondrial NAD
PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e76938
Figure 5. Identification of FKSG76 and NMNAT3v1 expression under different cellular conditions. (A) Immunoprecipitation of NMNAT3
from mitochondrial extracts of HEK239 cells or FKSG76-transfected whole cell homogenate. VDAC is shown as a mitochondrial marker. (B) Dot-blot
evaluation of the sensitivity of anti-NMNAT3 antibody to recombinant FKSG76. (C) Schematic representation of the 59UTRs of FKSG76 and NMNAT3v1
cloned in the reported vector used in Luciferase reporter assay (See Methods); the uORF sequences are depicted in red. (D) Effect of uORFs or
mutated uORFs (Mut-uORFs) on translational efficiency. (E) Time-dependent accumulation of ubiquitinated-proteins in MG132-exposed (10 mM) cells.
Tubulin is shown as loading control. (F) Densitometric evaluation of ubiquitin accumulation shown in (E). (G) Western blotting evaluation of FKSG76
and NMNAT3v1 expression in HEK cells after different times of exposure to the proteasome inhibitor MG132. Positive control for FKSG76 or
NMNAT3v1 are shown. Tubulin is shown as loading control. (H) Transcript levels of NMNAT1,22 and23 at different times after heat shock (44uC/309).
Note that for NMNAT3 analysis primers able to amplify a common region of NMNAT3v1 and FKSG76 have been used. Columns represent the mean6
SEM of 3 experiments. Western blotting or Dot-blot are representative of at least 3 experiments.* p,0.05; ** p,0.01; *** p,0.001 vs control
(Student’s t test).
doi:10.1371/journal.pone.0076938.g005
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checked whether the dinucleotide or its precursors added to the
culture media were able to prevent NAD depletion in cells
transfected with FKSG76.
Intriguingly, we found that cellular NAD depletion could be
completely prevented by adding 1 mM NAD to the culture media
(Fig. 6A). However, identical concentrations of the NAD
precursors Nam, NMN, nicotinamide riboside and nicotinic acid
were not effective (Fig. 6A). By means of the mitoPARP1cd assay,
we also investigated whether exogenous NAD and its precursors
prevented mitochondrial NAD depletion. Again, we found that
exogenous NAD fully prevented reduction of PAR formation in
mitochondria of cells co-transfected with FKSG76 and mito-
PARP1cd, an effect not mimicked by NAD precursors (Fig. 6B,
6C). Evidence that the NAD effects were not reproduced by its
precursors, suggested that NAD directly crosses the mitochondrial
to maintain the organelle’s NAD contents. To further corroborate
this assumption, we then reasoned that if mitochondrial NAD
formation occurs by matrix condensation of NMN with ATP by
NMNAT activity, then mitochondrial ATP depletion should
impair intraorganelle NAD biosynthesis. To verify this hypothesis,
we blocked mitochondrial ATP formation with the F1Fo ATP
synthase inhibitor oligomycin. The latter almost completely
reduced ATP contents in cells cultured in the absence of glucose
(Fig. 6D), in keeping with inhibition of mitochondrial ATP
formation. Notably, under these conditions the ability of
exogenous NAD to increase intramitochondrial PAR formation
in mitoPARP1cd-transfected cells was unaffected (fig. 6E, 6F),
suggesting that the NAD pool of mitochondria can be sustained by
direct entrance of cytosolic NAD, and does not require ATP-
dependent enzymatic steps.
Discussion
The present study sought to investigate the functional relevance
of NMNAT3 to mitochondrial NAD homeostasis. At variance
with prior information present in GenBank, we now report that a
single gene present on chromosome 3 codes for the two mRNA
splice variants NMNAT3v1 and FKSG76. However, we have
been unable to find molecular or functional evidence for
endogenous expression of the respective proteins. When transfect-
ed, NMNAT3v1 appears cytosolic and inactive, whereas FKSG76
localizes into mitochondria and reduces, rather than increases, the
organelle NAD content. Finally, we provide evidence that
exogenous NAD, but not its metabolic precursors, is able to
prevent mitochondrial NAD pool depletion caused by transfection
of FKSG76.
NMNAT3 has been first identified by means of sequence
homology with NMNAT1 [12]. Later on, almost all the
information collected on NMNAT3 localization and activity has
been obtained by expression plasmids coding for tagged proteins
[9,12,14]. The group of Magni, however, reported the presence of
NMNAT3 protein in human red blood cells. Intriguingly, as the
authors point out, reticulocytes undergo complex events of mRNA
maturation during differentiation that theoretically could underlie
cell-specific processing of pre-mRNA of nmnat3 [15]. An
additional study by Barile et al. reports the presence of NMNAT
activity in the mitochondrial matrix of rat hepatocytes [28]. It is
worth noting, however, that NADH rather than NAD was
measured in this as product of NMNAT. Furthermore, Barile and
associates report that exogenous NMN fuels mitochondrial
NMNAT activity only in conditions of organelle permeabilization
[28], indicating that the mononucleotide per se does not cross the
inner mitochondrial membrane. Although caution must be
exercised when interpreting these data as evidence for the
presence of a bona fide, mitochondrial NMNAT, recent work
suggests that cytosolic NMN is the precursor of mitochondrial
NAD [27]. In keeping with the study by Barile et al. [28], we
found a NAD-synthesizing activity from NMN and ATP in
mitochondrial extracts (Fig. 2E, 2F). However, given that
mitochondrial NMNAT activity is not affected by concomitant
silencing of FKSG76 and NMNAT3v1 (Fig. 2E) and NMNAT
activity is present in HeLa cells in spite of lack of NMNAT3
transcripts (Fig. 2G), an alternative interpretation should be put
forward. In particular, mitochondria might contain an enzymatic
activity, possibly belonging to the superfamily of nucleotidyltrans-
ferasea/bphosphodiesterases [29], able to catalyze nucleotidyla-
tion of NMN but with a different physiological role. In keeping
with this hypothesis, Km of mitochondrial NMNAT activity for
NMN reported by Barile and coworkers [28] is 18,2 mM whereas
that of recombinant NMNAT3 is 209 mM [9].
Data obtained by means of FKSG76 overexpression in control
or mitoPARP1cd-transfected cells indicate that this protein is
indeed targeted to mitochondria but operates in a reverse mode
(i.e. NAD cleavage). Of note, this finding is in good agreement
with prior work indicating that Vmax of FKSG76 for NAD
cleavage is almost 4-fold higher than that for NAD synthesis (12.8
and 3.6 mmol/min/mg prot, respectively) [9]. Exact knowledge of
concentrations of free ATP, NMN, NAD and PPi within the
mitochondrial matrix is currently lacking. However, the poor
permeability of mitochondrial membrane to NMN [28] may limit
the availability of this NMNAT3 substrate within the organelle.
This homeostatic conditions, together with substantial mitochon-
drial content of NAD and PPi, could well explain why FKSG76
operates in a reverse mode when artificially present in mitochon-
dria. In light of the key role of NAD in mitochondrial respiration
and overall organelle functioning, it is also conceivable that a
protein able to deplete the mitochondrial NAD pool such as
FKSG76 can severely jeopardize organelle homeostasis and cell
survival. Accordingly, we found that endogenous FKSG76 cannot
be detected by Western blotting or immunoprecipitation, suggest-
ing that it is not translated. Dot blot analysis demonstrated that the
antibody used to detect the two NMNAT3 isoforms has a
threshold sensitivity in the range of 0.5 ng. This is consistent with
sensitivity of antibodies normally used for Western blotting, and
further suggests that FKSG76 and NMNAT3v1 are not expressed.
Of course, we cannot rule out the possibility that these two
proteins are expressed at a very low level, that, however, is not of
functional significance (as the silencing experiments indicate). Still,
even a very recent, elegant proteomic approach able to identify the
whole mitochondrial proteome does not report NMNAT3 among
the organelle proteins [30]. In keeping with lack of FKSG76 and
NMNAT3v1 protein expression, in the 59UTR of their mRNAs
we identified a common uORF that reduces translational
efficiency of the downstream ORFs. The quantitative impact of
this uORF on endogenous FKSG76 and NMNAT3v1 translation
is unknown. Still, considering that it is able to significantly impair
luciferase expression driven by the very potent SV40 promoter, we
reason that its negative impact on physiological FKSG76 and
NMNAT3v1 expression should be of functional significance.
Accordingly, complete uORF-dependent suppression of protein
expression is reported [24]. Interestingly, the high degree of
conservation of uORF start codons in humans is considered as
evidence of key, albeit unknown, functional roles [23,24]. We
speculate that a possible reason for presence of uORF in
transcripts of NMNAT3 variants is that of preventing FKSG76-
expression within mitochondria and ensuing deleterious NAD
depletion. Alternatively, these transcripts might be long-non
coding RNAs playing unknown regulatory roles, in keeping with
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the notion that almost two thirds of RNA molecules are non-
coding transcripts within the cell [31,32]. Although further work is
needed to better understand why transcripts for the two NMNAT3
variants are present in HEK cells without being translated, our
finding showing that they are also present in various human tissues
at different levels underscores their potential functional relevance.
A widely appreciated dogma of cell biology is that mitochondria
are impermeable to NAD [16,33]. Several findings, however,
indicate that this tenet should be revisited. First, both yeast and
Figure 6. Effect of exogenous NAD or its precursors on cellular and mitochondrial NAD. (A) Quantification of NAD in control or FKSG67-
transfected HEK cells. The effect of NAD, nicotinamide (Nam), NMN, nicotinamide riboside (NR) or nicotinic acid (NA) on NAD contents of FKSG-
transfected cells is shown (NAD and its precursors have been added to the incubating media at 1 mM for 48 hrs). Basal NAD content was
12.662 nmol/mg prot. (B) Western blotting evaluation of the effect of NAD, Nam, NMN, NR or nicotinic acid NA (1 mM/48 hrs) on depletion of
mitochondrial PAR content induced by FKSG76 co-transfection in mitoPARP1cd-transfected cells. Tubulin is shown as loading control. (C)
Densitometric analysis on the experiment shown in (B). (D) Effect of oligomycin (10 mM/30 min) and/or glucose deprivation (30 min) on cellular ATP
contents. (E) Effects of exogenous NAD (1 mM/3 hrs) on mitochondrial PAR contents in mitoPARP1cd-transfected cells under control conditions or
exposed to oligomycin (10 mM) in the presence or absence of glucose. (F) Densitometric analysis on the experiment shown in (E). Columns represent
the mean 6 SEM of 3 experiments. Western blotting is representative of 3 (E) and 4 (C) experiments.* p,0.05; ** p,0.01 vs control (Student’s t test).
doi:10.1371/journal.pone.0076938.g006
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plant mitochondria have NAD transporters [34,35]. Second,
transporters for NAD precursors in the plasmamembrane or
different cell organelles including mitochondria have not been
identified so far. Third, inability of mitochondria to transport
NAD has been only demonstrated in vitro, and it might be due to
the fact that, under these experimental settings, transport systems
are impaired or lack a co- or counter-molecule necessary for their
functioning. Consistently, both yeast and plant mitochondrial
NAD transporters work as nucleotide exchangers [34,35]. Fourth,
increase in the extracellular concentrations of NAD in cultured
cells raises the dinucleotide content within their mitochondria and
boosts cellular respiration [8]. Finally, prior work found evidence
for metabolic state-dependent NAD fluxes through the inner
mitochondrial membrane [36,37]. These findings taken together,
plus data of the present study indicating that exogenous NAD but
not NMN, NR, NA or Nam prevents FKSG76-dependent
mitochondrial NAD depletion, suggest that, akin to yeast and
plants, yet-to-be defined mitochondrial NAD transporters are
present in mammalian cells. Accordingly, we also found that
increases of mitochondrial NAD pool by cytoplasmic NAD do not
depend from matrix ATP contents. Data showing that mitochon-
drial NMNAT3 is absent in the organelle and cleaves NAD when
artificially expressed further strengthen the hypothesis that the
mitochondrial NAD pool is of cytoplasmic origin.
In the next future it will be worth investigating possible
regulatory roles of non-coding FKSG76 and NMNAT3v1
mRNAs, as well as molecular identity of mammalian mitochon-
drial NAD transporters.
Supporting Information
Figure S1 Initial sequences of the ORF of FKSG76 and
NMNAT3v1 plus a portion of their 59UTR. The initial ORF
sequence of FKSG76 is shown in yellow (mitochondrial targeting
sequence) and blue, whereas that of NMNAT3v1 is shown in blue.
The final sequence of the 59UTR of FKSG76 is shown in violet
and red, whereas that of NMNAT3v1 is shown in violet and green.
The ATG of the uORF is underlined at the beginning of the violet
sequence.
(PDF)
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